stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) EV/FCF
As of 6 November 2026, Ionis Pharmaceuticals, Inc. (IONS) trades at a EV/FCF of −11.0×. Over the past ten years it has ranged from −1,542× (January 2021) to 762× (December 2015); the current reading is higher than 49% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −36.1× | — |
| FY2024 | −7.7× | — |
| FY2023 | −19.4× | — |
| FY2022 | −108× | — |
| FY2021 | 292× | — |
| FY2020 | −1,346× | — |
| FY2019 | 21.8× | 123.26% |
| FY2018 | 9.8× | (76.62%) |
| FY2017 | 41.8× | — |
| FY2016 | −45.1× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −22.6× | — |
| Mar 2026 | −12.5× | — |
| Dec 2025 | −36.1× | — |
| Sep 2025 | −28.6× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AXSM Axsome Therapeutics, Inc. compare | −79.7× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −79.2× |
| ORKA Oruka Therapeutics, Inc. compare | −51.4× |
| KOD Kodiak Sciences Inc. compare | −35.4× |
| CGON CG Oncology, Inc. compare | −26.2× |
| MIRM Mirum Pharmaceuticals, Inc. compare | −21.1× |
| IMVT Immunovant, Inc. compare | −12.2× |
| IONS Ionis Pharmaceuticals, Inc. | −10.9× |
| LGND Ligand Pharmaceuticals Incorporated compare | 60.7× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement